A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa.

Trial Profile

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease; Sleep disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms EASE-PD Adjunct
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 15 Sep 2009 Results were reported at the 13th Congress of the European Federation of Neurological Societies.
    • 13 Jun 2008 FDA approval received, based primarily on results from this study, according to a media release from GSK.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top